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Diabetes mellitus, preexisting coronary heart disease, and the
risk of subsequent coronary heart disease events in patients
infected with human immunodeficiency virus: the Data
Collection on Adverse Events of Anti-HIV Drugs (D:A:D Study)
Abstract
BACKGROUND: Although guidelines in individuals not infected with the human immunodeficiency
virus (HIV) consider diabetes mellitus (DM) to be a coronary heart disease (CHD) equivalent, there is
little information on its association with CHD in those infected with HIV. We investigated the impact of
DM and preexisting CHD on the development of a new CHD episode among 33,347 HIV-infected
individuals in the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D Study). METHODS
AND RESULTS: Over 159,971 person-years, 698 CHD events occurred. After adjustment for gender,
age, cohort, HIV transmission, ethnicity, family history of CHD, smoking, and calendar year, the rate of
a CHD episode was 7.52 times higher (Poisson regression, 95% CI 6.02 to 9.39, P=0.0001) in those with
preexisting CHD than in those without preexisting CHD, but it was only 2.41 times higher (95% CI 1.91
to 3.05, P=0.0001) in those with preexisting DM compared with those without DM. No statistical
interactions were apparent between either diagnosis and sex; although older people with DM had an
increased CHD rate compared with younger people, older people with preexisting CHD had a lower
event rate. A statistically significant interaction between preexisting DM and CHD (P=0.003) suggested
that the CHD rate in those with preexisting CHD and DM is lower than expected on the basis of the
main effects alone. CONCLUSIONS: DM and preexisting CHD are both important risk factors for CHD
events in HIV-infected individuals. There is a need for targeted interventions to reduce the risk of CHD
in both high-risk groups of HIV-infected individuals.
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Diabetes Mellitus, Preexisting Coronary Heart Disease, and
the Risk of Subsequent Coronary Heart Disease Events in
Patients Infected With Human Immunodeficiency Virus
The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D Study)
Signe W. Worm, MD; Stephane De Wit, PhD; Rainer Weber, MD; Caroline A. Sabin, PhD;
Peter Reiss, PhD; Wafaa El-Sadr, PhD; Antonella D’Arminio Monforte, DMSc; Ole Kirk, DMSc;
Eric Fontas, MD; Francois Dabis, PhD; Matthew G. Law, PhD; Jens D. Lundgren, DMSc;
Nina Friis-Møller, PhD
Background—Although guidelines in individuals not infected with the human immunodeficiency virus (HIV) consider diabetes
mellitus (DM) to be a coronary heart disease (CHD) equivalent, there is little information on its association with CHD in those
infected with HIV. We investigated the impact of DM and preexisting CHD on the development of a new CHD episode
among 33 347 HIV-infected individuals in the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D Study).
Methods and Results—Over 159 971 person-years, 698 CHD events occurred. After adjustment for gender, age, cohort,
HIV transmission, ethnicity, family history of CHD, smoking, and calendar year, the rate of a CHD episode was 7.52
times higher (Poisson regression, 95% CI 6.02 to 9.39, P0.0001) in those with preexisting CHD than in those without
preexisting CHD, but it was only 2.41 times higher (95% CI 1.91 to 3.05, P0.0001) in those with preexisting DM
compared with those without DM. No statistical interactions were apparent between either diagnosis and sex; although
older people with DM had an increased CHD rate compared with younger people, older people with preexisting CHD
had a lower event rate. A statistically significant interaction between preexisting DM and CHD (P0.003) suggested
that the CHD rate in those with preexisting CHD and DM is lower than expected on the basis of the main effects alone.
Conclusions—DM and preexisting CHD are both important risk factors for CHD events in HIV-infected individuals. There
is a need for targeted interventions to reduce the risk of CHD in both high-risk groups of HIV-infected individuals.
(Circulation. 2009;119:805-811.)
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Diabetes mellitus (DM) is an important risk factor forcoronary heart disease (CHD). In the National Choles-
terol Education Program guidelines,1 DM is considered to be
a “CHD risk equivalent,” which means that it is believed that
a diagnosis of DM places a patient at similar risk of a future
episode of CHD as a prior CHD episode. Several sources of
evidence support this paradigm,2–5 although others do not.6–9
Editorial p 770
Clinical Perspective p 811
In those infected with human immunodeficiency virus
(HIV), the underlying cause and origin of DM may differ
from that of the general population. For example, DM is a
known complication of several antiretroviral therapies, being
associated with both short-term10,11 and longer-term12,13 ex-
posure to some of these drugs. Lipodystrophy is associated
with insulin resistance and, in some cases, overt DM.14–16 The
reported prevalence of DM in HIV-infected populations
ranges from 2% to 14%, with differences in prevalence
explained by differences in demographic characteristics, life-
style, and antiretroviral exposure.17–20
Among those infected with HIV, the risk of myocardial
infarction (MI) is more than doubled in those with DM.21,22
With the aging of the HIV-infected population, brought about
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by an increased life expectancy after the use of combination
antiretroviral therapy, the prevalence of DM is likely to
increase. A more thorough understanding of the impact of
DM on CHD risk in those infected with HIV and how this risk
compares with that associated with preexisting CHD may
have major public health implications. Thus, the purpose of
the present study is to describe the predictive value of
preexisting DM and CHD for subsequent CHD events among
HIV-infected patients in the Data Collection on Adverse
Events of Anti-HIV Drugs (the D:A:D study).
Methods
Study Population
The D:A:D study is a prospective, observational study formed by the
collaboration of 11 cohorts following up 33 347 HIV-infected
subjects at 212 clinics in Europe, Australia, and the United States.
The primary objective of the study is to investigate the possible
association between combination antiretroviral therapy and the risk
of MI. The D:A:D study methodology has been described in detail
elsewhere.22,23
Data Collection
Patients are followed up prospectively during visits to outpatient
clinics as a part of regular medical care. At enrollment and at least
every 8 months, standardized data collection forms are completed at
the sites that provide information relating to physical status; family
history of CHD; prior history of cardiovascular disease and DM;
cigarette smoking; blood pressure; the use of lipid-lowering, antihy-
pertensive, and antiplatelet therapy; the presence of clinical signs of
lipodystrophy as defined by the physician; and serum lipid levels
(total cholesterol, HDL cholesterol, and triglycerides, including
information on whether values were obtained under fasting condi-
tions), as well as HIV-related information (antiretroviral therapy,
CD4 cell counts, HIV viral loads, and dates of diagnoses of all
AIDS-defining diseases).
Ascertainment of Outcomes
All incident cases of MI, invasive procedures involving the coronary
arteries (angioplasty or bypass), and all deaths (irrespective of cause)
are reported to the coordinating office for validation and coding, as
described in previous reports from the study.17,24 DM has been
collected as a secondary D:A:D end point since the start of the study.
All prospectively documented cases of DM are verified centrally by
the submission of a case report form. New-onset DM was defined in
1 of 2 ways: A definite diagnosis of DM if a fasting plasma glucose
7.0 mmol/L (126 mg/dL) was measured on 2 consecutive occa-
sions, or a possible diagnosis if the patient had a physician-reported
date of DM onset and was known to have initiated antidiabetes
therapy. For the purposes of the present analyses, definite and
possible diagnoses were combined.
Statistical Methods
We considered the incidence of a new/recurrent CHD event in
patients with or without preexisting CHD at study entry and in
patients with or without DM at study entry. For these analyses, a
CHD event was deemed to have occurred on the date of the earliest
of an MI, an invasive coronary procedure, or death due to CHD.
Patients who had already experienced an MI (266 patients) or
coronary revascularization (bypass: 52 patients; angioplasty: 131
patients) before study entry were defined as having preexisting CHD.
These events were not validated centrally. Follow-up time was
counted from the date of study entry to the date of a CHD episode;
death due to non-CHD causes; February 1, 2007; or 6 months after
the patient’s last clinic visit, whichever occurred first. Only the first
CHD event during prospective follow-up was considered in the
analyses.
In exploratory analyses, the rate of CHD was compared in the 4
groups defined by preexisting CHD and DM at study entry (ie, no
CHD or DM; DM but no CHD; CHD but no DM; and both CHD and
DM) with multivariable Poisson regression. The subgroup with no
preexisting CHD or DM was treated as the reference group for these
analyses, which were also adjusted for gender, age, cohort, HIV
transmission mode, ethnicity, family history of CHD, smoking, and
calendar year. These methods assume that within each calendar
period, the risk of a CHD event is constant over time. We then fitted
a Poisson regression model that included the main effects of each
diagnosis, as well as other potential confounding factors. We
explored whether any associations between preexisting DM or CHD
and the development of CHD differed by sex and age by incorpo-
rating interaction terms with preexisting DM/CHD and female sex
and older age (defined as 45 years in men and 55 years in
women). We then assessed whether the prognostic value of either
diagnosis differed according to the presence or absence of the
other diagnosis by incorporating an interaction term between the
diagnoses.
Sensitivity analyses were performed to assess whether any re-
ported associations were modified by further adjustment for the use
of treatments to reduce the risk of CHD (ie, lipid-lowering, antihy-
pertensive, and antiplatelet medication) or by adjustment for the
latest HDL cholesterol (log-transformed) and triglyceride measure-
ments, both as continuous time-updated covariates. A further sensi-
tivity analysis assessed the associations between preexisting DM,
CHD, and fatal cardiovascular disease, in which this end point was
deemed to have occurred if a patient died within 28 days of an MI,
stroke, or coronary revascularization. Finally, sensitivity analysis
considered a narrower CHD outcome that was based on the devel-
opment of MI or CHD-related death only (ie, coronary revascular-
ization events were excluded from the outcome).
As a further analysis, we then assessed whether the association
between DM and the development of CHD differed according to the
length of time that an individual had been diagnosed with DM. For
these analyses, we included all preexisting diagnoses of DM at study
entry and new diagnoses of DM that occurred over prospective
follow-up. Patient follow-up time and the occurrence of events were
classified into 4 groups according to the time since DM diagnosis:
(1) No diagnosis of DM; (2) a diagnosis of DM after study entry but
in the last 2 years; (3) a diagnosis of DM after study entry but 2
years previously; and (4) a diagnosis of DM before study entry. This
variable was incorporated into a Poisson regression model as a
time-updated covariate to allow patients to move between categories
as the time from their DM diagnosis lengthened, and it was adjusted
for all variables listed previously, including CHD at baseline.
The authors had full access to and take full responsibility for the
integrity of the data. All authors have read and agree to the
manuscript as written.
Results
Of the 33 347 patients included in the study, 352 (1.1%) had
preexisting CHD at study entry and 952 (2.9%) had preex-
isting DM. When split into the 4 groups defined on the basis
of the presence or absence of each of these diagnoses at study
entry, 296 (0.9%) patients had CHD but no DM, 896 (2.7%)
had DM but no CHD, and 56 (0.2%) had both diagnoses at
study entry. The characteristics of patients at entry into
D:A:D, stratified by their CHD and DM status, are shown in
Table 1.
Patients with either DM or CHD at entry in D:A:D were
more likely to be male and were older than their counterparts
without these events at study entry. Patients with DM or CHD
also had higher levels of total cholesterol and triglycerides
and lower HDL cholesterol levels than those without these
events, and those with CHD in particular had received more
medical interventions with lipid-lowering, antiplatelet and
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antihypertensive drugs. Greater proportions of patients with
DM or CHD had lipodystrophy. Patients with preexisting
CHD were more likely to have a family history of cardiovas-
cular disease than those without preexisting CHD. Although
exposure to antiretroviral therapy was generally greater in
those with preexisting CHD or DM, the differences in
duration of exposure were relatively small.
Incidence of CHD
Overall, 698 patients experienced an episode of CHD over
159 971 person-years of follow-up (rate 4.4 per 1000 person-
years, 95% CI 4.0 to 4.7). The distribution of events, stratified
by the 4 baseline groups, is shown in Table 2.
Among patients with preexisting CHD, the rates of a
recurrent CHD episode were 101.9 (95% CI 58.3 to 145.5)
and 76.4 (95% CI 60.8 to 92.0) per 1000 person-years,
respectively, in those with and without DM at study entry.
Conversely, in patients without preexisting CHD, the rates of
a new CHD episode were 16.4 (95% CI 12.5 to 20.3) and 3.4
(95% CI 3.1 to 3.6) per 1000 person-years, respectively, in
those with and without DM at study entry. Compared with
patients with no preexisting CHD or DM (the reference
group), patients with preexisting CHD were at substantially
higher risk of experiencing a recurrent episode of CHD
regardless of whether they did (adjusted relative risk [RR]
11.66, 95% CI 7.42 to 18.32, P0.0001) or did not (adjusted
RR 9.04, 95% CI 7.10 to 11.49, P0.0001) have DM at study
entry (Figure). In contrast, the increased risk of an event in
those who had preexisting DM but no CHD at study entry,
although statistically significant, was smaller (adjusted RR
3.03, 95% CI 2.34 to 3.93, P0.001). In a regression model
that included the main effects of each covariate (and adjust-
ment for other confounders), the adjusted relative risk of a
recurrent CHD episode associated with preexisting CHD was
7.52 (95% CI 6.02 to 9.39, P0.0001) whereas that associ-
ated with preexisting DM was 2.41 (95% CI 1.91 to 3.05,
P0.0001). In these models, there was no evidence that the
association between DM and the risk of CHD differed
according to sex (P value for interaction with female sex
0.85), although the association between DM and CHD ap-
peared to be stronger in older people than in younger people
(RR in older people 2.48, 95% CI 1.93 to 3.18; RR in younger
people 1.88, 95% CI 0.97 to 3.66; P for interaction0.004).
In contrast, although there was no evidence that the associa-
tion between preexisting CHD and the risk of a subsequent
CHD event differed according to sex (P for interac-
Table 1. Characteristics of Patients at Entry in D:A:D According to CHD and DM Status at Study Entry
No DM or CHD (n32 099) CHD but No DM (n296) DM but No CHD (n896) DM and CHD (n56)
Age, y 38 (33–44) 51 (44–58) 48 (40–55) 57 (47–64)
Male sex 23651 (73.7) 273 (92.2) 722 (80.6) 46 (82.1)
CD4, cells/mm3 410 (250–600) 426 (264–585) 364 (203–575) 481 (318–614)
HIV RNA, log10 copies/mL 2.7 (1.7–4.2) 2.1 (1.7–3.5) 2.6 (1.7–4.1) 1.9 (1.7–4.0)
Transmission
Homosexual 13789 (43.0) 176 (59.5) 387 (43.2) 24 (42.9)
Heterosexual 9682 (30.2) 65 (22.0) 282 (31.5) 18 (32.1)
Intravenous drug use 5824 (18.1) 21 (7.1) 102 (11.4) 4 (7.1)
Current smoker 10996 (34.3) 108 (36.5) 196 (21.9) 16 (28.6)
Ex-smoker 5334 (16.6) 96 (32.4) 175 (19.5) 12 (21.4)
Family history of CVD 2114 (6.6) 66 (22.3) 63 (7.0) 7 (12.5)
Exposed to each drug class; median (IQR) years
of exposure
PIs 18441 (57.5) 216 (73.0) 629 (70.2) 46 (82.1)
Median (IQR) years of exposure 2.3 (1.2–3.2) 2.6 (1.6–3.4) 2.5 (1.6–3.4) 2.7 (1.9–3.2)
NRTIs 23251 (72.4) 257 (86.8) 742 (82.8) 49 (87.5)
Median (IQR) years of exposure 3.0 (1.6–4.7) 4.0 (2.3–5.7) 3.9 (2.3–5.8) 4.2 (3.4–5.5)
NNRTIs 10501 (32.7) 138 (46.6) 396 (44.2) 28 (50.0)
Median (IQR) years of exposure 0.9 (0.4–1.6) 1.0 (0.4–1.7) 1.0 (0.4–1.7) 1.2 (0.8–1.8)
Lipodystrophy 5817 (18.1) 92 (31.1) 303 (33.8) 24 (42.9)
TC, mmol/L 4.9 (4.1–5.8) 5.5 (4.7–6.4) 5.4 (4.4–6.3) 5.6 (4.9–6.3)
TG, mmol/L 1.6 (1.0–2.6) 2.2 (1.4–3.5) 2.4 (1.4–4.0) 3.0 (1.8–4.4)
HDL, mmol/L 1.1 (0.9–1.4) 1.0 (0.8–1.2) 1.0 (0.8–1.3) 0.9 (0.8–1.5)
Antihypertensive drugs 1062 (3.3) 152 (51.4) 164 (18.3) 27 (48.2)
Antiplatelet drugs 289 (0.9) 149 (50.3) 41 (4.6) 26 (46.4)
Lipid-lowering drugs 1091 (3.4) 118 (39.9) 123 (13.7) 19 (33.9)
CVD indicates cardiovascular disease; IQR, interquartile range; PI, protease inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside
transcriptase inhibitor; TC, total cholesterol; and TG, triglycerides.
Table entries are n (%) or median (IQR) as appropriate.
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tion0.42), the association between preexisting CHD and a
recurrent CHD event was weaker in older than in younger
people (RR in older people 6.06, 95% CI 4.72 to 7.78; RR in
younger people 26.07, 95% CI 16.70 to 40.69; P for interac-
tion0.0001). Both interactions with older age remained
unchanged after adjustment for the use of interventions
(lipid-lowering, antiplatelet, and antihypertensive
medication).
To more formally investigate whether the effect of each
diagnosis on a subsequent event differed according to the
presence or absence of the other diagnosis, we included a
statistical interaction term between the 2 diagnoses. The
statistical interaction between the 2 was significant (interac-
tion RR 0.43, 95% CI 0.25 to 0.75, P0.003), which suggests
that the rate of CHD in those with CHD and DM at study
entry was lower than would be expected on the basis of the
main effects alone. Further analyses then explored the effect
of incorporating the use of medical interventions (lipid-
lowering therapy, antihypertensive, and antiplatelet medica-
tion) and, in a separate model, the impact of adjustment for
the latest triglyceride and HDL cholesterol levels; neither
adjustment altered our main conclusions (data not shown).
When we considered associations with fatal cardiovascular
disease (242 events), we again found a greater impact of
preexisting CHD compared with that of DM, although dif-
ferences were smaller than in the main analysis (Table 3).
Compared with patients without preexisting DM or CHD,
those with preexisting CHD were at 4.61 times (95% CI 2.82
to 7.53, P0.0001) the risk of a new event if they did not
have preexisting DM and at 11.12 (95% CI 5.75 to 21.50,
P0.0001) times the risk if they did. Patients without
preexisting CHD but with DM were at 2.82 (95% CI 1.84 to
4.32, P0.0001) times the risk of a new event compared with
those with neither diagnosis at baseline.
Additional sensitivity analyses in which coronary revascu-
larizations were excluded as a component of the composite
end point (Table 3) again reached similar conclusions: Pa-
tients with preexisting CHD were at a much higher risk of a
recurrent episode of CHD regardless of whether they did
(10.62, 95% CI 6.04 to 18.67, P0.0001) or did not (4.73,
95% CI 3.32 to 6.75, P0.0001) have DM at study entry. In
contrast, those with preexisting DM but not CHD at study
entry were at 2.95 (95% CI 2.23 to 3.91, P0.0001) times the
risk of those with neither diagnosis at study entry.
Impact on Development of CHD of New Diagnoses
of DM
When all diagnoses of DM (including those that occurred
during follow-up) were incorporated, the CHD rate was 3.8
(95% CI 3.5 to 4.1) per 1000 person-years among patients
who were not diagnosed with DM. The CHD rate was higher
among patients diagnosed with DM, and this rate appeared to
increase with longer duration of DM; specifically, the rate
was 8.2 (95% CI 4.5 to 13.8) per 1000 person-years among
patients followed up within the first 2 years after DM
diagnosis, 11.6 (95% CI 6.2 to 19.9) per 1000 person-years
among those followed up for 2 years after DM (but in
whom the diagnosis was made after entry in D:A:D), and 20.5
(95% CI 16.2 to 24.8) per 1000 person-years among patients
with DM before entry in D:A:D. In multivariable analysis, the
adjusted RR of a CHD event associated with recent (ie, in the
last 2 years) DM diagnosis was 1.35 (95% CI 0.79 to 2.31,
Table 2. Distribution of First Recurrent CHD Episode Occurring During Follow-Up, Stratified by Each Patient’s CHD and DM Status at
Entry in D:A:D
Status at Entry in D:A:D
No DM or CHD (n32 099) CHD but No DM (n296) DM but No CHD (n896) DM and CHD (n56)
PYFU
Total 154 417 1205 4142 206
Median (IQR) 5.1 (3.3–6.6) 4.3 (2.3–6.3) 5.0 (3.1–6.5) 3.8 (0.9–6.5)
No. with event over follow-up period 517 92 68 21
Event rate/1000 PYFU (95% CI) 3.4 (3.1–3.6) 76.4 (60.8–92.0) 16.4 (12.5–20.3) 101.9 (58.3–145.5)
Type of event, n (% of those with an event)
MI 395 (76.4) 50 (54.4) 50 (73.5) 16 (76.2)
Angioplasty 80 (15.5) 26 (28.3) 10 (14.7) 4 (19.1)
Bypass 20 (3.9) 14 (15.2) 7 (10.3) 1 (4.8)
CHD death 22 (4.3) 2 (2.2) 1 (1.5) 0 (  )
PYFU indicates person-years of follow-up; IQR, interquartile range.
Figure. Adjusted RR of CHD episode in patients according to
history of CHD or DM. Adjustment for gender, age, cohort, HIV
transmission mode, ethnicity, family history of CHD, smoking,
and calendar year.
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P0.27) compared with patients who did not have DM. The
adjusted RR of a CHD event among patients diagnosed with
DM for 2 years was 2.30 (95% CI 1.32 to 4.02, P0.003).
Finally, the adjusted RR of a CHD event among patients with
a diagnosis of DM before D:A:D enrollment was 2.49 (95%
CI 1.97 to 3.15, P0.0001).
Discussion
The D:A:D study currently contains information on 33 000
HIV-infected patients followed up for almost 160 000 person-
years. Although the increased risk of a CHD event associated
with preexisting CHD was substantially greater than that
associated with DM, which appears not to support the
paradigm that DM is a CHD risk equivalent in this popula-
tion, both diagnoses were associated with a substantial
increase in risk. Thus, there is a need for targeted interven-
tions to reduce the risk of CHD events in these 2 high-risk
groups. In particular, the present finding that the risk of CHD
increased with longer duration of DM emphasizes the impor-
tance of regular screening for this potentially modifiable
condition.
Although the present findings appeared to show a weaker
association between DM and CHD than between preexisting
CHD and subsequent CHD events, several points should be
taken into consideration. First, unlike the participants in the
general population studies that have considered this issue,
who were often in their 50s, the HIV-infected patients
included in the D:A:D study are younger (usually in their 30s
or 40s). As in the HIV-uninfected population, age is an
important risk factor for both DM and CHD in those with
HIV infection,21,23 and the relative prognostic importance of
these 2 diagnoses may change as the population ages. Second,
DM in HIV-infected individuals is not only caused by the
mechanisms seen in the general population (eg, obesity,
physical inactivity, and genetic predisposition) but may also
result from the use of antiretroviral therapy. Drugs from both
the protease inhibitor and nucleoside reverse transcriptase
inhibitor classes may each contribute to insulin resistance and
DM through different mechanisms.16,25,26 The mitochondrial
dysfunction caused by the thymidine analogues within the
nucleoside reverse transcriptase inhibitor drug class results in
insulin resistance both in healthy volunteers and in HIV-
infected patients even in the absence of overt lipodystro-
phy.27–29 In addition, the HIV-infected population has a
different risk profile for both DM and CHD than the general
population, with a greater prevalence of smoking22,30,31 and
coinfection with hepatitis C virus32,33 but a lower prevalence
of obesity.30 Third, in the present study, the risk of CHD
increased with longer duration of DM. The relatively recent
onset of DM (an average time since diagnosis of 5 years) may
be insufficient to cause macrovascular damage, which would
result in a weaker association between DM and CHD than
that seen in the general population.34–36 Indeed, studies of
recently diagnosed diabetic patients tend to report weaker
associations with CHD.37,38 If the CHD outcomes are re-
stricted to fatal events, then it is likely that any apparent
impact of DM will be greater,4,5,39 as we have also reported
here in a sensitivity analysis.
Compared with patients without preexisting CHD, patients
with a history of CHD had received more “prophylactic”
interventions, including invasive cardiovascular disease pro-
cedures, lipid-lowering drugs, and antihypertensive medica-
tion; however, the use of these interventions remained sub-
optimal in these high-risk individuals, particularly in those
with DM. Adjustment for the use of these interventions did
not modify our conclusions. Furthermore, a sensitivity anal-
ysis in which we excluded coronary revascularizations from
the composite end point reached similar conclusions.
We found that although the association between DM and
CHD was stronger in older people than in younger people, the
opposite was true for the association between preexisting and
recurrent CHD. Although it is possible that this association
may simply reflect a chance finding, older people with
preexisting CHD may survive for a shorter time after their
initial CHD event than younger individuals, leaving them at
risk of a new event for less time. Alternatively, the use of
secondary interventions40 may be more common in older
people, leading to a reduction in risk.
Study Limitations
The present study definition of definite DM is conservative
compared with the definition recommended in the American
Diabetes Association guidelines,41,42 which could have led to
an underestimation of the number of DM events in the present
study. Unfortunately, the D:A:D study does not collect
detailed data on insulin resistance or anthropometrics, which
means that we were unable to investigate whether some
Table 3. Adjusted RR* of New CHD Event in Patients According to History of CHD or DM
No DM or CHD RR (95% CI) CHD but No DM RR (95% CI) DM but No CHD RR (95% CI) DM and CHD RR (95% CI)
Primary analysis† 1 9.04 (7.10–11.49) 3.03 (2.34–3.93) 11.66 (7.42–18.30)
P 0.0001 0.0001 0.0001
Excluding invasive procedures‡ 1 4.73 (3.32–6.75) 2.95 (2.23–3.91) 10.62 (6.04–18.67)
P 0.0001 0.0001 0.0001
Only fatal CVD§ 1 4.61 (2.82–7.53) 2.82 (1.84–4.32) 11.12 (5.75–21.50)
P 0.0001 0.0001 0.0001
CVD indicates cardiovascular disease.
*Includes adjustment for gender, age, cohort, HIV transmission mode, ethnicity, family history of CHD, smoking, and calendar year.
†Composite end point of MI, invasive procedures, and deaths due to CHD.
‡MI and deaths due to CVD only.
§Deaths that occurred within 28 days after an MI, a stroke, and invasive procedures.
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patients not having DM actually had pre-DM, which may also
increase the risk of CHD.37
In conclusion, both DM and preexisting CHD are impor-
tant risk factors for subsequent CHD events in the HIV-
infected population. There is evidence to suggest that DM is
becoming an increasing problem among those infected with
HIV, and we have recently reported an increase of DM
among patients under follow-up from 3.8% in 1999/2000 to
5.2% in 2005/2006.43 Furthermore, we recently reported that
only one fifth of patients with DM in the D:A:D study who
were not taking lipid-lowering drugs initiated such primary
prevention.40 Thus, we suggest that targets for interventions
among HIV-infected individuals should consider an individ-
ual’s entire risk factor profile, including their history of CHD
and DM.
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CLINICAL PERSPECTIVE
With the aging of the human immunodeficiency virus (HIV)–infected population, brought about by an increased life
expectancy after the widespread use of combination antiretroviral therapy, it is likely that the prevalence of diabetes
mellitus (DM) will increase. DM is an important risk factor for coronary heart disease (CHD) in HIV-infected populations.
Among those infected with HIV, the risk of myocardial infarction is more than doubled in those with DM; however, it is
currently unknown whether the CHD risk attributable to DM in patients with HIV infection is similar to that observed in
the general HIV-uninfected population. In the present large, international HIV observational study with 33 000 patients,
it was demonstrated that the risk for CHD over 5 years was 7.52 times as high in those with preexisting CHD and 2.41
times as high in those with preexisting DM as in those patients without preexisting diseases. Our study acknowledges the
importance of DM; in particular, our finding that the risk of CHD increased with longer duration of DM emphasizes the
importance of regular screening for this potentially modifiable condition. Guidelines on the prevention of CHD should be
based on data from randomized, controlled trials, but our data emphasize the need for targeted interventions to reduce the
risk of CHD in HIV-infected individuals with DM. Thus, we suggest that targets for interventions among HIV-infected
individuals should consider an individual’s entire risk factor profile, including their history of CHD and DM.
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participating physicians(city, state):  R. Luskin-Hawk (Chicago, Illinois); E. Telzak 
(Bronx, New York); W.M. El-Sadr (Harlem, New York); D.I. Abrams (San Francisco, 
California); D. Cohn (Denver, Colorado); N. Markowitz (Detroit, Michigan); R. Arduino 
(Houston, Texas); D. Mushatt (New Orleans, Louisiana); G. Friedland (New Haven, 
Connecticut); G. Perez (Newark, New Jersey); E. Tedaldi (Philadelphia, Pennsylvania); 
E. Fisher (Richmond, Virginia); F. Gordin (Washington, DC); L.R. Crane (Detroit, 
Michigan); J. Sampson (Portland, Oregon); J. Baxter (Camden, New Jersey).  
 
EuroSIDA (multinational):  
Coordinating Centre Staff: J Lundgren (project leader), O Kirk, A Mocroft, N Friis-
Møller, A Cozzi-Lepri, W Bannister, M Ellefson, A Borch, D Podlekareva, J Kjær, L 
Peters, J Reekie 
Argentina: (M Losso), A Duran, Hospital JM Ramos Mejia, Buenos Aires.  
Austria: (N Vetter) Pulmologisches Zentrum der Stadt Wien, Vienna.  
Belarus: (I Karpov), A Vassilenko, Belarus State Medical University, Minsk, VM Mitsura, 
Gomel State Medical University, Gomel; O Suetnov, Regional AIDS Centre, Svetlogorsk.  
Belgium: (N Clumeck) S De Wit, B Poll, Saint-Pierre Hospital, Brussels; R Colebunders, 
Institute of Tropical Medicine, Antwerp  
Bulgaria: K Kostov, Infectious Diseases Hospital, Sofia.  
Croatia: J Begovac, University Hospital of Infectious Diseases, Zagreb.  
Czech Republic: (L Machala) H Rozsypal, Faculty Hospital Bulovka, Prague; D 
Sedlacek, Charles University Hospital, Plzen. 
Denmark: (J Nielsen) J Lundgren, T Benfield, O Kirk, Hvidovre Hospital, Copenhagen; J 
Gerstoft, T Katzenstein, A-B E Hansen, P Skinhøj, Rigshospitalet, Copenhagen; C 
Pedersen, Odense University Hospital, Odense, L Oestergaard, Skejby Hospital, 
Aarhus.  
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Estonia: (K Zilmer) West-Tallinn Central Hospital, Tallinn, Jelena Smidt, 
Nakkusosakond Siseklinik, Kohtla-Järve.  
Finland: (M Ristola), Helsinki University Central Hospital, Helsinki.  
France: (C Katlama) Hôpital de la Pitié-Salpétière, Paris; J-P Viard, Hôpital Necker-
Enfants Malades, Paris; P-M Girard, Hospital Saint-Antoine, Paris; JM Livrozet, Hôpital 
Edouard Herriot, Lyon; P Vanhems, University Claude Bernard, Lyon; C Pradier, Hôpital 
de l'Archet, Nice; F Dabis, Unité INSERM, Bordeaux.  
Germany: (J Rockstroh) Universitäts Klinik Bonn; R Schmidt, Medizinische Hochschule 
Hannover; J van Lunzen, O Degen, University Medical Center Hamburg-Eppendorf, 
Infectious Diseases Unit, Hamburg; HJ Stellbrink, IPM Study Center, Hamburg; S 
Staszewski, JW Goethe University Hospital, Frankfurt; J Bogner, Medizinische Poliklinik, 
Munich; G. Fätkenheuer, Universität Köln, Cologne.  
Greece: (J Kosmidis) P Gargalianos, G Xylomenos, J Perdios, Athens General Hospital; 
G Panos, A Filandras, E Karabatsaki, 1st IKA Hospital; H Sambattakou, Ippokration 
Genereal Hospital, Athens.  
Hungary: (D Banhegyi) Szent Lásló Hospital, Budapest. 
Ireland: (F Mulcahy) St. James's Hospital, Dublin.  
Israel: (I Yust) D Turner, M Burke, Ichilov Hospital, Tel Aviv; S Pollack, G Hassoun, 
Rambam Medical Center, Haifa;S Maayan, Hadassah University Hospital, Jerusalem.  
Italy: (A Chiesi) Istituto Superiore di Sanità, Rome; R Esposito, I Mazeu, C Mussini, 
Università Modena, Modena; C Arici, Ospedale Riuniti, Bergamo; R Pristera, Ospedale 
Generale Regionale, Bolzano; F Mazzotta, A Gabbuti, Ospedale S Maria Annunziata, 
Firenze; V Vullo, M Lichtner, University di Roma la Sapienza, Rome; A Chirianni, E 
Montesarchio, M Gargiulo, Presidio Ospedaliero AD Cotugno, Monaldi Hospital, Napoli; 
G Antonucci, F Iacomi, P Narciso, C Vlassi, M Zaccarelli, Istituto Nazionale Malattie 
Infettive Lazzaro Spallanzani, Rome; A Lazzarin, R Finazzi, Ospedale San Raffaele, 
Milan; M Galli, A Ridolfo, Osp. L. Sacco, Milan; A d’Arminio Monforte,  Istituto Di Clinica 
Malattie Infettive e Tropicale, Milan. 
Latvia: (B Rozentale) P Aldins, Infectology Centre of Latvia, Riga.  
Lithuania: (S Chaplinskas) Lithuanian AIDS Centre, Vilnius.  
Luxembourg: (R Hemmer), T Staub, Centre Hospitalier, Luxembourg.  
Netherlands: (P Reiss) Academisch Medisch Centrum bij de Universiteit van 
Amsterdam, Amsterdam.  
Norway: (J Bruun) A Maeland, V Ormaasen, Ullevål Hospital, Oslo.  
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Poland: (B Knysz) J Gasiorowski, Medical University, Wroclaw; A Horban, Centrum 
Diagnostyki i Terapii AIDS, Warsaw; D Prokopowicz, A Wiercinska-Drapalo, Medical 
University, Bialystok; A Boron-Kaczmarska, M Pynka, Medical Univesity, Szczecin; M 
Beniowski, E Mularska, Osrodek Diagnostyki i Terapii AIDS, Chorzow; H Trocha, 
Medical University, Gdansk.  
Portugal: (F Antunes) E Valadas, Hospital Santa Maria, Lisbon; K Mansinho, Hospital 
de Egas Moniz, Lisbon; F Maltez, Hospital Curry Cabral, Lisbon.  
Romania: (D Duiculescu) Spitalul de Boli Infectioase si Tropicale: Dr. Victor Babes, 
Bucarest.  
Russia: (A Rakhmanova), Medical Academy Botkin Hospital, St Petersburg; E 
Vinogradova, St Petersburg AIDS Centre, St Peterburg; S Buzunova, Novgorod Centre 
for AIDS, Novgorod.  
Serbia: (D Jevtovic), The Institute for Infectious and Tropical Diseases, Belgrade. 
Slovakia: (M Mokráš) D Staneková, Dérer Hospital, Bratislava.  
Spain: (J González-Lahoz) V Soriano, L Martin-Carbonero, P Labarga, Hospital Carlos 
III, Madrid; B Clotet, A Jou, J Conejero, C Tural, Hospital Germans Trias i Pujol, 
Badalona; JM Gatell, JM Miró, Hospital Clinic i Provincial, Barcelona; P Domingo, M 
Gutierrez, G Mateo, MA Sambeat, Hospital Sant Pau, Barcelona.  
Sweden: (A Karlsson), Karolinska University Hospital, Stockholm; PO Persson, 
Karolinska University Hospital, Huddinge; L Flamholc, Malmö University Hospital, 
Malmö.  
Switzerland: (B Ledergerber) R Weber, University Hospital, Zürich; P Francioli, M 
Cavassini, Centre Hospitalier Universitaire Vaudois, Lausanne; B Hirschel, E Boffi, 
Hospital Cantonal Universitaire de Geneve, Geneve; H Furrer, Inselspital Bern, Bern; M 
Battegay, L Elzi, University Hospital Basel.  
Ukraine: (E Kravchenko) N Chentsova, Kiev Centre for AIDS, Kiev.  
United Kingdom: (S Barton) St. Stephen's Clinic, Chelsea and Westminster Hospital, 
London; AM Johnson, D Mercey, Royal Free and University College London Medical 
School, London (University College Campus); A Phillips, MA Johnson, A Mocroft, Royal 
Free and University College Medical School, London (Royal Free Campus); M Murphy, 
Medical College of Saint Bartholomew's Hospital, London; J Weber, G Scullard, Imperial 
College School of Medicine at St. Mary's, London; M Fisher, Royal Sussex County 
Hospital, Brighton; R Brettle, Western General Hospital, Edinburgh. 
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HivBivus (Sweden):  
Central coordination: L. Morfeldt*, G. Thulin, A. Sundström;  
participating physicians(city): B. Åkerlund (Huddinge); K. Koppel, A. Karlsson 
(Stockholm); L. Flamholc, C. Håkangård (Malmö).  
 
ICONA (Italy):  
Central coordination: A. d’Arminio Monforte*, P. Pezzotti;  
PARTICIPATING PHYSICIANS AND CENTERS 
Italy M. Montroni, G. Scalise, A Costantini, A. Riva (Ancona); U. Tirelli, F. Martellotta 
(Aviano-PN); G. Pastore, N. Ladisa, (Bari); F. Suter, F. Maggiolo (Bergamo); F. Chiodo, 
V. Colangeli, C. Fiorini, (Bologna); G. Carosi, G. Cristini, C. Torti, C. Minardi, D. Bertelli 
(Brescia); T. Quirino, (Busto Arsizio); P.E. Manconi, P. Piano (Cagliari); E. Pizzigallo, M. 
D’Alessandro (Chieti); G Carnevale, A Zoncada (Cremona); F. Ghinelli, L. Sighinolfi 
(Ferrara); F. Leoncini, F. Mazzotta, M. Pozzi, S. Lo Caputo (Firenze); B. Grisorio, S. 
Ferrara (Foggia); G. Pagano, G. Cassola, A. Alessandrini, R. Piscopo (Genova); F. 
Soscia, L. Tacconi (Latina); A. Orani, P. Perini (Lecco); D Tommasi, P Congedo (Lecce); 
F. Chiodera, P. Castelli (Macerata); M. Moroni, A. Lazzarin, G. Rizzardini, L. Caggese, 
A. d’Arminio Monforte, A. Galli, S. Merli, C. Pastecchia, M.C. Moioli (Milano); R. 
Esposito, C. Mussini (Modena); A Gori, S Cagni (Monza), N. Abrescia, A. Chirianni, CM 
Izzo, M. De Marco, R. Viglietti, E Manzillo (Napoli); C. Ferrari, P. Pizzaferri (Parma); G. 
Filice, R. Bruno, (Pavia); G. Magnani, M.A. Ursitti (Reggio Emilia); M. Arlotti, P. Ortolani 
(Rimini); R. Cauda, M Andreoni, A. Antinori, G. Antonucci,  P. Narciso, V Tozzi, V. Vullo, 
A. De Luca, M. Zaccarelli, R. Acinapura, P. De Longis, M.P. Trotta, M. Lichtner, F. 
Carletti, (Roma); M.S. Mura, M. Mannazzu (Sassari); P. Caramello, G. Di Perri, G.C. 
Orofino, M. Sciandra (Torino); E. Raise, F. Ebo (Venezia); G. Pellizzer, D. Buonfrate 
(Vicenza). 
 
 
The Nice Cohort (France):  
Central coordination: C. Pradier*, E. Fontas, C. Caissotti;  
participating physicians: P. Dellamonica, L. Bentz, E. Bernard, , F. De Salvador-
Guillouet, J. Durant, V. Mondain-Miton, I. Perbost, B. Prouvost-Keller, P. Pugliese, V. 
Rahelinirina, P.M. Roger, F. Vandenbos.  
 
SHCS (Swiss HIV Cohort Study, Switzerland): M. Battegay, E. Bernasconi, J. Böni, H. 
Bucher, Ph. Bürgisser, S. Cattacin, M. Cavassini, R.Dubs, M. Egger, L.Elzi, P. Erb,  
M. Fischer, M. Flepp, A. Fontana, P. Francioli (President of the SHCS), H.J. Furrer, 
M. Gorgievski, H. Günthard, B. Hirschel, L. Kaiser, C. Kind, Th. Klimkait, U. Lauper, 
B. Ledergerber, M. Opravil, F. Paccaud, G. Pantaleo, L. Perrin, J.-C. Piffaretti, M. 
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Rickenbach, C. Rudin P. Schmid, J. Schüpbach, R. Speck, A. Telenti, A. Trkola,  P. 
Vernazza, R. Weber*, S. Yerly. 
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